Bio-Path Holdings Q1 2024 GAAP EPS $(4.88) Misses $(4.54) Estimate
Portfolio Pulse from Benzinga Newsdesk
Bio-Path Holdings reported a Q1 2024 GAAP EPS of $(4.88), missing the estimate of $(4.54).
May 15, 2024 | 10:06 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bio-Path Holdings reported a Q1 2024 GAAP EPS of $(4.88), which is worse than the estimated $(4.54). This earnings miss could negatively impact the stock price in the short term.
The reported EPS of $(4.88) is significantly below the estimated $(4.54), indicating worse-than-expected financial performance. This is likely to lead to a negative market reaction and a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100